Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Valproate in Acute Ischemic Stroke
NCT06020898Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Sodium valproate group with Placebo group (2 arms). Primary endpoint: Favorable outcome at 90 days (mRS score <= 2). Started Sep 2023; status: recruiting.
02
Drugs
valproic acid
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06020898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020898.